SCHEMBL1316616

SCHEMBL1316616

Nc1cccc2c(=O)[nH][nH]c(=O)c12.[Na]

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.96
KDM4E B2RXH2 2/20 0.46
LMNA P02545 1/20 0.46
PKM P14618 1/20 0.46
PARP1 P09874 8/20 0.46
TDP1 Q9NUW8 3/20 0.46
RECQL P46063 2/20 0.46
JAK2 O60674 1/20 0.44
RPS6KA3 P51812 1/20 0.44
MELK Q14680 1/20 0.44
STK24 Q9Y6E0 1/20 0.44
ALOX5 P09917 1/20 0.43
DAO P14920 1/20 0.42
CYP3A4 P08684 2/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TYMS P04818 1/20 0.40
MEN1 O00255 2/20 0.39
POLB P06746 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29419148 1.00 ALDH1A1 (0.96) ALDH1A1KDM4ELMNAPKMPARP1
SCHEMBL20086 0.98 ALDH1A1 (1.00) ALDH1A1KDM4ELMNAPKMPARP1
SCHEMBL27034083 0.98 ALDH1A1 (1.00) ALDH1A1KDM4ELMNAPKMPARP1
SCHEMBL29448530 0.98 ALDH1A1 (1.00) ALDH1A1KDM4ELMNAPKMPARP1
SCHEMBL25429670 0.96 ALDH1A1 (0.96) ALDH1A1KDM4ELMNAPKMPARP1
Lithium SCHEMBL1315235 0.96 ALDH1A1 (0.96) ALDH1A1KDM4ELMNAPKMPARP1
Potassium SCHEMBL1315293 0.96 ALDH1A1 (0.96) ALDH1A1KDM4ELMNAPKMPARP1
Hydrochloric Acid SCHEMBL7117065 0.96 ALDH1A1 (0.96) ALDH1A1KDM4ELMNAPKMPARP1
Water SCHEMBL18317911 0.96 ALDH1A1 (0.96) ALDH1A1KDM4ELMNAPKMPARP1
SCHEMBL49588 0.96 ALDH1A1 (0.96) ALDH1A1KDM4ELMNAPKMPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
US-12616695-B2 Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases METRIOPHARM AG (CH) 2026-05-05 US claimed
US-20260060981-A1 COMBINATION OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AND A FUMARIC ACID ESTER METRIOPHARM AG (CH) 2026-03-05 US claimed
EP-4701641-A1 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR THE PROPHYLAXIS AND TREATMENT OF THROMBOTIC DISORDERS MetrioPharm AG (CH) 2026-03-04 EP claimed
EP-4164651-B1 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR USE IN THE TREATMENT OF CORONAVIRAL INFECTIONS METRIOPHARM AG (CH) 2025-10-15 EP claimed
EP-4125802-B1 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR TREATMENT OF ACUTE LUNG INJURY METRIOPHARM AG (CH) 2025-10-01 EP claimed
WO-2025067689-A1 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE FOR THE TREATMENT OF INFECTIONS WITH AN RNA VIRUS METRIOPHARM AG (CH) 2025-04-03 WO claimed
US-20250064801-A1 USE OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE IN THE TREATMENT OF CONGENITAL MUSCULAR DYSTROPHIES METROPHARM AG (CH) 2025-02-27 US claimed
US-20250064800-A1 COMBINATION OF BUDESONIDE AND 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE METROPHARM AG (CH) 2025-02-27 US claimed
EP-4178579-B1 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AS GLUCOCORTICOID-SPARING AGENT METRIOPHARM AG (CH) 2025-02-12 EP claimed
US-20140113902-A1 METHOD FOR OBTAINING 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE Abidopharma PL SP. Z.O.O. (PL) 2014-04-24 US claimed
US-8536171-B2 Method for obtaining 5-amino 2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine Abidopharma PL SP. Z.O.O. (PL) 2013-09-17 US claimed
US-20120329801-A1 CRYSTALLINE FORMS FOR 5-AMINO-2, 3-DIHYDROPHTHALAZINE-1, 4-DIONE SODIUM SALT, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AND METHOD FOR THE PRODUCTION OF SAID FORMS METRIOPHARM AG (CH) 2012-12-27 US claimed
EP-2389364-A2 NEW METHOD FOR OBTAINING 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE Abidopharma Pl SP. Z.O.O (PL) 2011-11-30 EP claimed
US-20110275642-A1 NEW METHOD FOR OBTAINING 5-AMINO 2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE Abidopharma PL SP. Z.O.O. (PL) 2011-11-10 US claimed
US-8039605-B2 Targeting of long chain triacylglycerol hydrolase gene for tuberculosis treatment UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2011-10-18 US claimed
WO-2010082858-A2 NEW METHOD FOR OBTAINING 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE ABIDOPHARMA PL SP. Z.O.O (PL) 2010-07-22 WO claimed
US-20020198208-A1 MEDICINAL PREPARATION AND PROCESS FOR MANUFACTURING THEREOF ABIDOV, MUSA TAZHUDINOVICH (RU) 2002-12-26 US claimed
US-6489326-B1 SODIUM NUCLEINATE, 2-AMINO-1,2,3,4-TETRAHYDROPHTHALAZINE-1,4-DIONE SODIUM SALT DIHYDRATE, USED AS AN IMMUNOMODULATOR, WHICH ALSO HAS ANTIINFLAMMATORY AND ANTIOXIDANT PROPERTIES Pavlov, Anatoliy Ivanovich (RU) 2002-12-03 US claimed
EP-1203587-A1 A MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF Abidov, Musea Tazhudinovich (RU) 2002-05-08 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275642-A1 NEW METHOD FOR OBTAINING 5-AMINO 2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE ADH1C, SCN5A, ADH1A ALDH1A1 91/4885KDM4E 2263/4885LMNA 2703/4885
US-20120329801-A1 CRYSTALLINE FORMS FOR 5-AMINO-2, 3-DIHYDROPHTHALAZINE-1, 4-DIONE SODIUM SALT, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AND METHOD FOR THE PRODUCTION OF SAID FORMS IL5, DCUN1D5, SCN5A ALDH1A1 741/4885KDM4E 2824/4885LMNA 4640/4885
US-12616695-B2 Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases CRYZ, PDE12, FKBP5 ALDH1A1 515/4885KDM4E 4154/4885LMNA 1580/4885
US-20140113902-A1 METHOD FOR OBTAINING 5-AMINO-2,3-DIHYDROPHTHALAZINE-1,4-DIONE ALKALI METAL SALTS AND THEIR USE IN MEDICINE SCN5A, SLC5A2, KCNJ2 ALDH1A1 1348/4885KDM4E 1852/4885LMNA 1352/4885
US-20260060981-A1 COMBINATION OF 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AND A FUMARIC ACID ESTER IL5, IL17A, IL15 ALDH1A1 901/4885KDM4E 1048/4885LMNA 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.